The presentation will look at the early development of the company who were formed in the toughest market conditions technology companies have experienced. Utilising a strong intellectual property base coupled to a management team with substantial international experience the company has developed a collaboration strategy which has brought early revenues whilst still focusing on its core development plans. With a developing portfolio of antibody technologies and platforms and a number of exciting lead compounds in in vivo studies the company is now poised for rapid growth. Novel approaches utilisaing human therapeutic antibodies have been developed in the company's core areas of anti-infectives and CNS disease